Speaker Name: Prof. Steve Bain, Assistant Medical Director for Research & Development for Swansea Bay University, Swansea University, Wales, UK.

Access this expert session to:

• Understand the progressive loss of β-cell function in T2DM and why many patients ultimately require insulin therapy.
• Compare ADA/EASD and NICE guideline recommendations on the timing and role of insulin initiation in T2DM management.
• Review how basal, premix, prandial, and basal-bolus insulin regimens can be individualized to patient needs, glycemic targets, and clinical scenarios.
• Recognize the impact of therapeutic inertia, delayed insulin initiation, and common misconceptions on long-term glycemic outcomes.
• Evaluate evidence from UKPDS, 4T, and ORIGIN trials supporting the efficacy, safety, biosimilar use, and early initiation of insulin in selected patients.